Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

Sex- and age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes.

Uno Y, Takata R, Kito G, Yamazaki H, Nakagawa K, Nakamura Y, Kamataki T, Katagiri T.

Drug Metab Pharmacokinet. 2017 Feb;32(1):100-107. doi: 10.1016/j.dmpk.2016.10.409. Epub 2016 Oct 27.

PMID:
28153492
2.

Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Kazuki Y, Akita M, Kobayashi K, Osaki M, Satoh D, Ohta R, Abe S, Takehara S, Kazuki K, Yamazaki H, Kamataki T, Oshimura M.

Sci Rep. 2016 Feb 23;6:21419. doi: 10.1038/srep21419.

3.

Cytochrome P450 2A6 phenotyping based on dietary caffeine intake in a Japanese population of non-smokers.

Kimura M, Shimizu M, Kiyotani K, Nakagawa K, Kamataki T, Yamazaki H.

Drug Metab Lett. 2012 Jun 1;6(2):67-72.

PMID:
22849705
4.

Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway.

Nakada T, Kiyotani K, Iwano S, Uno T, Yokohira M, Yamakawa K, Fujieda M, Saito T, Yamazaki H, Imaida K, Kamataki T.

J Toxicol Sci. 2012;37(3):555-63.

5.

Human cytochrome P450 1A1 is a novel target gene of liver X receptor α.

Shibahara N, Masunaga Y, Iwano S, Yamazaki H, Kiyotani K, Kamataki T.

Drug Metab Pharmacokinet. 2011;26(5):451-7. Epub 2011 Jun 7.

6.

Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method.

Azuma K, Lezhava A, Shimizu M, Kimura Y, Ishizu Y, Ishikawa T, Kamataki T, Hayashizaki Y, Yamazaki H.

Clin Chim Acta. 2011 Jun 11;412(13-14):1249-51. doi: 10.1016/j.cca.2011.03.017. Epub 2011 Mar 21.

PMID:
21420395
7.

Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Nagano T, Shimizu M, Kiyotani K, Kamataki T, Takano R, Murayama N, Shono F, Yamazaki H.

Int J Environ Res Public Health. 2010 Jul;7(7):2953-64. doi: 10.3390/ijerph7072953. Epub 2010 Jul 20.

8.

Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.

Kiyotani K, Shimizu M, Kumai T, Kamataki T, Kobayashi S, Yamazaki H.

Eur J Clin Pharmacol. 2010 Oct;66(10):1065-8. doi: 10.1007/s00228-010-0876-4. Epub 2010 Aug 11.

PMID:
20700584
9.

Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.

Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T.

Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.

PMID:
19845430
10.

8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.

Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Kuno T, Kamataki T, Imaida K.

Mol Med Rep. 2009 Jul-Aug;2(4):585-8. doi: 10.3892/mmr_00000141.

PMID:
21475870
11.

Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.

Matsunaga M, Yamazaki H, Kiyotani K, Iwano S, Saruwatari J, Nakagawa K, Soyama A, Ozawa S, Sawada J, Kashiyama E, Kinoshita M, Kamataki T.

Drug Metab Dispos. 2009 Apr;37(4):699-701. doi: 10.1124/dmd.108.026096. Epub 2009 Jan 21.

PMID:
19158312
12.
13.

Sex-related differences in the expression of mfGSTA2, a novel GST identified in cynomolgus monkey (Macaca fascicularis).

Uno Y, Ohuchi T, Uehara S, Kito G, Kamataki T, Nagata R.

Drug Metab Dispos. 2009 Mar;37(3):453-6. doi: 10.1124/dmd.108.023747. Epub 2008 Dec 16.

PMID:
19088266
14.

A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism.

Uno Y, Sakuraba H, Uehara S, Kumano T, Matsuno K, Nakamura C, Kito G, Kamataki T, Nagata R.

Drug Metab Dispos. 2009 Jan;37(1):14-7. doi: 10.1124/dmd.108.023622. Epub 2008 Sep 29.

PMID:
18824522
15.

Polymer-induced phase separation in aqueous micellar solutions of octyl-beta-D-thioglucoside for extraction of membrane proteins.

Tani H, Saitoh T, Kamidate T, Kamataki T, Watanabe H.

Biotechnol Bioeng. 1997 Nov 5;56(3):311-8. doi: 10.1002/(SICI)1097-0290(19971105)56:3<311::AID-BIT9>3.0.CO;2-M.

PMID:
18636647
16.

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y.

Cancer Sci. 2008 May;99(5):1049-54. doi: 10.1111/j.1349-7006.2008.00773.x.

17.

Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?

Uno Y, Hosaka S, Matsuno K, Nakamura C, Kito G, Kamataki T, Nagata R.

Arch Biochem Biophys. 2007 Oct 1;466(1):98-105. Epub 2007 Jul 14.

PMID:
17689485
18.

Overexpression of CYP2A6 in human colorectal tumors.

Matsuda Y, Saoo K, Yamakawa K, Yokohira M, Suzuki S, Kuno T, Kamataki T, Imaida K.

Cancer Sci. 2007 Oct;98(10):1582-5. Epub 2007 Aug 7.

19.

CYP2A6 overexpression in human lung cancers correlates with a high malignant status.

Matsuda Y, Yamakawa K, Saoo K, Hosokawa K, Yokohira M, Kuno T, Iwai J, Shirai T, Obika K, Kamataki T, Imaida K.

Oncol Rep. 2007 Jul;18(1):53-7.

PMID:
17549345
20.

Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology.

Mitani Y, Lezhava A, Kawai Y, Kikuchi T, Oguchi-Katayama A, Kogo Y, Itoh M, Miyagi T, Takakura H, Hoshi K, Kato C, Arakawa T, Shibata K, Fukui K, Masui R, Kuramitsu S, Kiyotani K, Chalk A, Tsunekawa K, Murakami M, Kamataki T, Oka T, Shimada H, Cizdziel PE, Hayashizaki Y.

Nat Methods. 2007 Mar;4(3):257-62. Epub 2007 Feb 18.

PMID:
17322893
21.

In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.

Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K.

Drug Metab Pharmacokinet. 2006 Dec;21(6):475-84.

22.

CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans.

Uno Y, Kumano T, Kito G, Nagata R, Kamataki T, Fujino H.

Xenobiotica. 2007 Jan;37(1):30-43.

PMID:
17178632
23.

[How I was enticed into molecular toxicology].

Kamataki T.

Yakugaku Zasshi. 2006 Dec;126(12):1309-18. Review. Japanese.

24.

Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Saruwatari J, Matsunaga M, Ikeda K, Nakao M, Oniki K, Seo T, Mihara S, Marubayashi T, Kamataki T, Nakagawa K.

Eur J Clin Pharmacol. 2006 Dec;62(12):995-1001. Epub 2006 Nov 7.

PMID:
17089107
25.

Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population.

Yamazaki H, Fujita H, Gunji T, Zhang J, Kamataki T, Cashman JR, Shimizu M.

Mol Genet Metab. 2007 Jan;90(1):58-63. Epub 2006 Sep 25.

PMID:
16996766
26.

Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level.

Sarikaya D, Bilgen C, Kamataki T, Topcu Z.

Biopharm Drug Dispos. 2006 Nov;27(8):353-9.

PMID:
16894644
27.

Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans.

Kuribayashi S, Ueda N, Naito S, Yamazaki H, Kamataki T.

Xenobiotica. 2006 Apr;36(4):301-14.

PMID:
16684710
28.

CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone.

Uno Y, Fujino H, Kito G, Kamataki T, Nagata R.

Mol Pharmacol. 2006 Aug;70(2):477-86. Epub 2006 Apr 28.

PMID:
16648389
29.

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.

Cancer Chemother Pharmacol. 2006 Oct;58(4):494-503. Epub 2006 Jan 25.

PMID:
16437251
30.

Activation of p53 as a causal step for atherosclerosis induced by polycyclic aromatic hydrocarbons.

Iwano S, Shibahara N, Saito T, Kamataki T.

FEBS Lett. 2006 Feb 6;580(3):890-3. Epub 2006 Jan 19.

31.

CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons.

Iwano S, Asanuma F, Nukaya M, Saito T, Kamataki T.

Biochem Biophys Res Commun. 2005 Nov 18;337(2):708-12. Epub 2005 Sep 26.

PMID:
16202979
32.

Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.

Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H.

Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10. Epub 2005 Sep 15. Review.

PMID:
16176798
33.

Predecessors of the giant 1960 Chile earthquake.

Cisternas M, Atwater BF, Torrejón F, Sawai Y, Machuca G, Lagos M, Eipert A, Youlton C, Salgado I, Kamataki T, Shishikura M, Rajendran CP, Malik JK, Rizal Y, Husni M.

Nature. 2005 Sep 15;437(7057):404-7.

PMID:
16163355
34.

[Tailor-made medicine].

Kamataki T.

Nihon Yakurigaku Zasshi. 2005 Jul;126(1):60-5. Review. Japanese. No abstract available.

PMID:
16141620
35.

A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons.

Iwano S, Nukaya M, Saito T, Asanuma F, Kamataki T.

Biochem Biophys Res Commun. 2005 Sep 16;335(1):220-6.

PMID:
16061200
36.

Mild trimethylaminuria observed in a Japanese cohort with liver damage.

Yamazaki H, Fujieda M, Cashman JR, Kamataki T.

Am J Med. 2005 Jul;118(7):803-5. No abstract available.

PMID:
15989923
37.

Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.

Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, Kamataki T.

Drug Metab Dispos. 2005 Sep;33(9):1361-6. Epub 2005 Jun 24.

PMID:
15980104
38.

Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.

Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K, Nohmi T, Funae Y, Imaida K, Kamataki T.

Carcinogenesis. 2005 Nov;26(11):1947-55. Epub 2005 Jun 15. Erratum in: Carcinogenesis. 2005 Dec;26(12):2214.

PMID:
15958517
39.

Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice.

Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Miyazaki M, Fujieda M, Kamataki T, Imaida K.

Cancer Lett. 2006 Mar 28;234(2):232-8.

PMID:
15893417
40.

Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.

Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T.

Biol Pharm Bull. 2005 May;28(5):882-5.

41.

Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.

Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T.

Xenobiotica. 2005 Jan;35(1):69-83.

PMID:
15788369
42.

Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.

Miyazaki M, Sugawara E, Yoshimura T, Yamazaki H, Kamataki T.

Mutat Res. 2005 Mar 7;581(1-2):165-71. Epub 2005 Jan 12.

PMID:
15725615
43.
44.

Novel gender-related regulation of CYP2C12 gene expression in rats.

Endo M, Takahashi Y, Sasaki Y, Saito T, Kamataki T.

Mol Endocrinol. 2005 May;19(5):1181-90. Epub 2005 Jan 20.

PMID:
15661834
45.

High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.

Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T.

Eur J Clin Pharmacol. 2005 Feb;60(12):855-7. Epub 2005 Jan 20.

PMID:
15660270
46.

Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese.

Fujieda M, Yamazaki H, Togashi M, Saito T, Kamataki T.

Drug Metab Pharmacokinet. 2003;18(5):333-5.

47.

Two novel haplotypes of CYP2D6 gene in a Japanese population.

Yamazaki H, Kiyotani K, Tsubuko S, Matsunaga M, Fujieda M, Saito T, Miura J, Kobayashi S, Kamataki T.

Drug Metab Pharmacokinet. 2003;18(4):269-71.

48.

Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese.

Saito T, Egashira M, Kiyotani K, Fujieda M, Yamazaki H, Kiyohara C, Kunitoh H, Kamataki T.

Drug Metab Pharmacokinet. 2003;18(3):218-21.

49.

Production of inhibitory polyclonal antibodies against cytochrome P450s.

Ng PS, Imaoka S, Hiroi T, Osada M, Niwa T, Kamataki T, Funae Y.

Drug Metab Pharmacokinet. 2003;18(3):163-72.

50.

Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.

Fujieda M, Yamazaki H, Kiyotani K, Muroi A, Kunitoh H, Dosaka-Akita H, Sawamura Y, Kamataki T.

Drug Metab Pharmacokinet. 2003;18(1):86-90.

Supplemental Content

Loading ...
Support Center